# Nebulized Heparin for COVID19-associated Acute Respiratory Failure

> **NCT04842292** · PHASE2 · TERMINATED · sponsor: **Brittany Bissell** · enrollment: 2 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Heparin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04842292
- **Lead sponsor:** Brittany Bissell
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-20
- **Primary completion:** 2021-09-04
- **Final completion:** 2021-09-04
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of enrollment
- **Last updated:** 2022-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04842292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04842292, "Nebulized Heparin for COVID19-associated Acute Respiratory Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04842292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*